All content for The Readout Loud is the property of STAT and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
378: Merck's heart disease win and the FDA's new drug regulator
The Readout Loud
36 minutes
1 week ago
378: Merck's heart disease win and the FDA's new drug regulator
What does Rick Pazdur's new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the president take for lowering GLP-1 drug prices?
Dean Li, the head of R&D at Merck, joins us to discuss the long-awaited trial results for the company's oral medicine targeting PCSK9 to lower cholesterol. These types of treatments have proven effective at addressing heart disease, but making them into more accessible pills has proven tricky.We also discuss the latest news in the life sciences, including the resolution of Pfizer and Novo Nordisk's bidding war over Metsera, Pazdur's new role at the FDA, and the end of a decade-long longevity venture.
The Readout Loud
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
